ASCO Annual Meeting

New data show a leukemia treatment working better in real patients than expected with response rates nearly double what trials showed. Here's what it could mean for you.

Updated COMMANDS trial data show Reblozyl improved survival and long-term transfusion independence vs. Epogen in lower-risk MDS patients.

Early ASCO data show emiltatug ledadotin produced durable responses in patients with aggressive adenoid cystic carcinoma.

Five-year KEYNOTE-942 data show a personalized cancer vaccine plus Keytruda reduced recurrence risk in patients with high-risk melanoma.

Monjuvi and Revlimid plus R-CHOP helped patients with high-risk diffuse large B-cell lymphoma stay in remission longer and reduce relapse risk.

Trodelvy plus Keytruda extended benefit beyond progression in PD-L1-positive metastatic triple-negative breast cancer.

Keytruda plus Lynparza showed clinical activity but missed its primary efficacy goal in BRCA-mutated metastatic pancreatic cancer.

Investigational bispecific antibody pumitamig achieved a 70% response rate and disease control in all evaluable patients with advanced NSCLC.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.

In a phase 3 study, Opdivo plus Yervoy did not improve overall survival when combined with chemotherapy for HER2-negative gastric or GEJ cancer.

Exercise after colon cancer chemotherapy reduced recurrence risk, improved survival and quality of life, according to the CHALLENGE trial.

ASCO 2026: Telephone-based weight loss significantly improves physical function and mental health in patients with breast cancer patients who are overweight or obese.

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy.

Giredestrant plus Afinitor improved disease control after later treatment and delayed chemotherapy in ER-positive, HER2-negative breast cancer.

Giredestrant plus Afinitor may help patients with metastatic breast cancer delay chemotherapy and stay on effective treatment longer.

Patients with cancer taking GLP-1 drugs alongside immunotherapy had better long-term survival and fewer immune-related side effects.

Study data shows Ibtrozi provides rapid symptom relief and stable brain health for patients with advanced ROS1-positive lung cancer.

Dr. Emily Podany links food deserts to aggressive breast cancer mutations and shorter survival, stressing the need for social determinant screening.

OPTIMA trial data at ASCO 2026 shows a 50-gene test helps patients with high-risk breast cancer avoid unnecessary and toxic chemotherapy treatments.

KEYNOTE-522 trial data shows adding Keytruda to chemotherapy drastically improves long-term survival for high-risk, early-stage TNBC.

ASCO 2026: MajesTEC-9 trial shows Tecvayli cuts death risk by 40% and improves outcomes in relapsed/refractory multiple myeloma patients.

Mezigdomide, Kyprolis and dexamethasone cut progression risk by 52% in relapsed or refractory multiple myeloma.

Blenrep produced strong responses and manageable side effects in transplant-ineligible patients with newly diagnosed multiple myeloma.

Lifyorli plus Abraxane improved survival in platinum-resistant ovarian cancer regardless of prior taxane use, according to updated ROSELLA data.

Sac-TMT plus Keytruda helped patients with PD-L1–positive advanced NSCLC live longer without their cancer worsening and increased response rates versus Keytruda alone.

Patients with EGFR exon 20-positive NSCLC had longer progression-free survival with Zegfrovy than chemotherapy.

ASCO 2026 will feature new gynecologic cancer research, including advances in immunotherapy, ADCs, vaccines and targeted therapies.

Discover five breakthrough breast cancer studies disrupting oncology as global research teams unveil practice-changing data at ASCO 2026 in Chicago.